| Identification | Back Directory | [Name]
6-KETO PROSTAGLANDIN F1ALPHA-D4 | [CAS]
82414-64-0 | [Synonyms]
KFGOFTHODYBSGM-GKZGVFJGSA-N
6-keto Prostaglandin F1α-d4
6-KETO PROSTAGLANDIN F1ALPHA-D4
6-KETO-PROSTAGLANDIN F1ALPHA-3,3,4,4-D4
6-OXO-9ALPHA,11ALPHA,15S-TRIHYDROXY-PROST-13E-EN-1-OIC-3,3,4,4-D4 ACID | [Molecular Formula]
C20H34O6 | [MDL Number]
MFCD00135270 | [MOL File]
82414-64-0.mol | [Molecular Weight]
370.49 |
| Chemical Properties | Back Directory | [solubility ]
DMF: >100 mg/ml (from 6-keto PGF1a); DMSO: >50 mg/ml (from 6-keto PGF1a); Ethanol: >16 mg/ml (from 6-keto PGF1a); PBS pH 7.2: >3.3 mg/ml (from 6-keto PGF1a |
| Hazard Information | Back Directory | [Description]
6-keto Prostaglandin F1α-d4 (6-keto PGF1α-d4) contains four deuterium atoms at the 3, 3'', 4, and 4'' positions. It is intended for use as an internal standard for the quantification of 6-keto PGF1α by GC- or LC-MS. 6-keto PGF1α is the inactive, non-enzymatic hydrolysis product of PGI2. 6-keto PGF1α serves as a useful marker of PGI2 biosynthesis in vivo. When [3H]-PGI2 is injected into healthy human males, 6.6% of the radioactivity is recovered from urine as [3H]-6-keto PGF1α. | [Uses]
6-keto Prostaglandin F1α-d4 is the deuterium labeled 6-keto Prostaglandin F1α[1]. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110 |
|
|